Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

June 20, 2020

Study Completion Date

September 30, 2020

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine

200 mg PO BID 7 days

DRUG

Indomethacin

50 mg PO TID 14 Days

DRUG

Zithromax Oral Product

500 mg PO QD 3 Days

Trial Locations (2)

70124

RECRUITING

Covidcraz 19, Llc, New Orleans

85254

RECRUITING

Perseverance Research Center, Scottsdale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Athena Medical Group

UNKNOWN

lead

Perseverance Research Center, LLC

OTHER

NCT04344457 - Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 | Biotech Hunter | Biotech Hunter